Drug-resistant Neisseria gonorrhoeae in Michigan

Emerging Infectious Diseases

Volumn 11, Issue 7, 2005, Pages 1009-1015

  Macomber, Kathryn E ^a,c   Boehme, Martha S ^a   Rudrik, James T ^a   Ganoczy, Dara ^b   Crandell Alden, Erin ^a   Schneider, William A ^a   Somsel, Patricia A ^a  

^a MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CIPROFLOXACIN; DOXYCYCLINE; QUINOLONE;

ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; DRUG SENSITIVITY; GONORRHEA; HUMAN; NEISSERIA GONORRHOEAE; REVIEW; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; UNITED STATES;

EID: 21144444419     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1107.041359     Document Type: Review

References (14)

1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2003 supplement: Gonococcal Isolate Surveillance Project (GISP) annual report-2003. Atlanta: US Department of Health and Human Services; 2004.
2. Centers for Disease Control and Prevention. Fluoroquinolone resistance in Neisseria gonorrhoeae, Hawaii, 1999. and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR Morb Mortal Wkly Rep. 2000;49:833.
3. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:1041.
4. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2002 supplement: Gonococcal Isolate Surveillance Project (GISP) annual report-2002. Atlanta: US Department of Health and Human Services; 2003.
5. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2001 supplement: Gonococcal Isolate Surveillance Project (GISP) annual report-2001. Atlanta: US Department of Health and Human Services; 2002.
6. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep. 2002;51(RR-6):1-78.
7. World Health Organization. Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeas in the WHO Western Pacific Region, 2001. Commun Dis Intell. 2002;26:541-5.
8. Dan M, Poch F, Sheinberg B. High prevalence of high-level ciprofloxacin resistance in Neisseria gonorrhoeas in Tel Aviv Israel: correlation with response to therapy. Antimicrob Agents Chemother. 2002;46:1671-3.
9. Sarwal S, Wong T, Sevigny C, Ng LK. Increasing incidence of ciprofloxacin-resistant Neisseria gonorrhoeae in Canada. CMAJ. 2003;168:872-3.
10. Centers for Disease Control and Prevention. Notice to readers: discontinuation of cefixime tablets-United States. MMWR Morb Mortal Wkly Rep. 2002;51:1052.
11. NCCLS. Performance standards for antimicrobial disk susceptibility tests; approved standard-eighth edition. NCCLS document M2-A8. Wayne (PA): The Committee; 2003.
12. NCCLS. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement. NCCLS document M100-S14. Wayne (PA): The Committee; 2004.
13. AB BIODISK. Etest technical guide 7. Susceptibility testing of gonococci. Piscataway (NJ): AB BIODISK North America, Inc.; 1997.
14. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men-United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:335-8.